Open AccessEvaluation of the efficacy of levocarnitine in supporting therapy in multiple myeloma
Author(s) -
Ozoda Achilova,
Gulchekhra Zukhriddinovna Makhamadalievа,
Элдор Исхаков
Publication year - 2021
Publication title -
society and innovations
Language(s) - English
Resource type - Journals
ISSN - 2181-1415
DOI - 10.47689/2181-1415-vol2-iss1-pp56-61
Subject(s) - toxicity , chemotherapy , medicine , hematology , multiple myeloma , oncology , pharmacology
The accompanying therapy prescribed during the use of toxic drugs helps patients to complete the treatment to the end, and the doctor adheres to the treatment of the chosen lineThe aim of the study was to study the effect of levocarnitine on blood biochemical parameters and on chemotherapy tolerance.Materials and methods. The study was conducted in the stem cell treatment department at Republican Specialized Scientific Practical Medical Center of Hematology . Chemotherapy toxicity was assessed according to WHO and NCIC standards.Results. In a comparative study, 30 patients receiving chemotherapy for myeloma with varying degrees of toxicity when fortecarnite (100 mg / kg / day) was added to standard therapy for 2 months or more showed a significant positive change in cytochemical parameters (Alanin transferase (ALT), aspartat transferase (AST)), which allowed the authors recommend metabolic correction to all patients receiving chemotherapy, especially with 2nd and 3rd degree of toxicity.